Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Regeneron Pharmaceuticals has announced the identification of hundreds of fully human antibodies against Covid-19, caused by the novel coronavirus.
The virus-neutralising antibodies came from Regeneron’s genetically-modified VelocImmune mice, which have an immune system similar to humans.
Furthermore, the company isolated antibodies from recovered Covid-19 patients. Regeneron plans to choose the top two antibodies to create a ‘cocktail’ therapy given as prophylaxis or a treatment for infected people.
Meanwhile, the company is using its VelociMab technology to formulate manufacturing-ready cell lines to enable immediate clinical-scale production of